Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar-Apr;40(4):648-651.
doi: 10.12669/pjms.40.4.8536.

Effects of combined sintilimab and chemotherapy on progression-free survival and overall survival in osteosarcoma patients with metastasis

Fan Li  1 , De-Bao Zhang  2 , Yue Ma  3 , Yang Song  4 , Xian-Liang Duan  5
Affiliations

Effects of combined sintilimab and chemotherapy on progression-free survival and overall survival in osteosarcoma patients with metastasis

Fan Li et al. Pak J Med Sci. 2024 Mar-Apr.

Abstract

Objective: To explore the safety and efficacy of metastatic osteosarcoma treatment with combined sintilimab injection and chemotherapy.

Methods: We performed a retrospective analysis of 32 patients with metastatic osteosarcoma admitted to the Affiliated Hospital of Beihua University between January 2019 and June 2020. The sample was divided into an observation group, treated with sintilimab injection combined with chemotherapy (n= 16) and a control group, treated with chemotherapy (n = 16). Clinical efficacy and adverse reactions were compared between the two groups.

Results: The overall response rates were 68.75% in the observation group and 31.25% in the control group (p < 0.05). The incidences of adverse reactions were 56.25% in the observation group and 81.25% in the control group. This was not a significant difference. In the observation group, the progression-free survival time was 8.13 ± 2.50 months, and the overall survival time was 22.75 ± 4.95 months. These were both significantly longer than the respective 6.44 ± 1.93 months and 19.69 ± 2.68 months in the control group (p < 0.05).

Conclusion: The treatment of metastatic osteosarcoma with combined sintilimab injection and chemotherapy was found to prolong progression-free survival and overall survival time without increasing the incidence of adverse reactions.

Keywords: Efficacy; Metastatic osteosarcoma; Sintilimab; safety.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: None.

References

    1. Flores RJ, Li Y, Yu A, Shen J, Rao PH, Lau SS, et al. A systems biology approach reveals common metastatic pathways in osteosarcoma. BMC Syst Biol. 2012;6:50. doi:10.1186/1752-0509-6-50. - PMC - PubMed
    1. Elbahri HMH, Abd-Elmaged HMA, Abdulkarim M, Ahmed MMM, Medani MME. Wide resection and reconstruction in a low resource area, cemented nail technique knee arthrodesis;a report of case and surgical technique. Int J Surg Case Rep. 2022;99:107621. doi:10.1016/j.ijscr.2022.107621. - PMC - PubMed
    1. Yang C, Tian Y, Zhao F, Chen Z, Su P, Li Y, et al. Bone Microenvironment and Osteosarcoma Metastasis. Int J Mol Sci. 2020;21(19):6985. doi:10.3390/ijms21196985. - PMC - PubMed
    1. Shoaib Z, Fan TM, Irudayaraj JMK. Osteosarcoma mechanobiology and therapeutic targets. Br J Pharmacol. 2022;179(2):201–217. doi:10.1111/bph.15713. - PMC - PubMed
    1. Zhang SY, Wang Y. Progress of programmed death receptor 1 and programmed death receptor ligand 1 inhibitors in the treatment of small cell lung cancer. Chin J of Oncol. 2021;43(1):98–103. doi:10.3760/cma.j.cn112152-20191218-00819. - PubMed

LinkOut - more resources